Treatment with novel oral anticoagulants: indications, efficacy and risks.

@article{Ghanny2013TreatmentWN,
  title={Treatment with novel oral anticoagulants: indications, efficacy and risks.},
  author={Shari Ghanny and Mark Crowther},
  journal={Current opinion in hematology},
  year={2013},
  volume={20 5},
  pages={
          430-6
        }
}
PURPOSE OF REVIEW To summarize data relevant to novel oral anticoagulants (nOACs), mainly apixaban, dabigatran and rivaroxaban, as alternatives to vitamin K antagonists (VKAs). RECENT FINDINGS RE-LY was the first contemporaneous study to compare a nOAC, dabigatran, with dose-adjusted warfarin, for prevention of stroke and systemic embolism in atrial fibrillation. Since then multiple studies have compared nOACs to warfarin for acute (RE-COVER, RECOVER-II, EINSTEIN-DVT and EINSTEIN-PE) and… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 18 CITATIONS